Working… Menu

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02427451
Recruitment Status : Active, not recruiting
First Posted : April 28, 2015
Last Update Posted : November 6, 2019
Information provided by (Responsible Party):
Kerry Rogers, Ohio State University Comprehensive Cancer Center